Korea’s Celltrion Will Support Hospira On EU Infliximab Sales While Setting Sights On Japan
This article was originally published in PharmAsia News
Executive Summary
How Celltrion and Hospira will share the European market remains to be seen, but Celltrion says the partners will support each other in taking on J&J’s Remicade. The Korean company also files for approval of infliximab in Japan, setting up another potential battleground on biosimilars.
You may also be interested in...
Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics
Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.
Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.